p21-Activated Kinases (PAKs) as a Therapeutic Target.
10.3342/kjorl-hns.2011.54.12.813
- Author:
Bon Seok KOO
1
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, Cancer Research Institute, Research Institute for Medical Sciences, Chungnam National University College of Medicine, Daejeon, Korea. bskoo515@cnuh.co.kr
- Publication Type:Review
- Keywords:
p21-activated kinases;
Neoplasms;
Protein kinase inhibitors;
Signal transduction
- MeSH:
Biomarkers;
Breast Neoplasms;
Cell Movement;
Cytoskeleton;
Extracellular Matrix;
Humans;
Monomeric GTP-Binding Proteins;
Ovarian Neoplasms;
p21-Activated Kinases;
Protein Kinase Inhibitors;
Protein Kinases;
Signal Transduction;
Stomach Neoplasms
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2011;54(12):813-818
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
p21-activated kinases (PAKs) are a family of serine/threonine protein kinases comprised of six isoform (PAK1-6), all of which are direct targets of the small GTPases Rac and Cdc42. PAKs have recently been shown to regulate various cellular activities, including cell motility, survival and proliferation, the organization and function of cytoskeleton and extracellular matrix, transcription and translation. PAKs are overexpressed or hyperactivated in several human tumor, such as breast cancer, gastric cancer, ovarian cancer etc., which makes them an attractive new therapeutic targets. Thus, there has been considerable interest in the development of inhibitors to the PAKs, as biological markers and leads for the development of therapeutics.
